Study for pathophysiological significance of insulin-like growth factor II
Study for pathophysiological significance of insulin-like growth factor II
批准号:
10671043
负责人:
HIZUKA Naomi
金额:
$2.05万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In this study, we have investigated pathophysiological significance of IGF-II as follows.1) Mechanism of hypoglycemia in non-islet cell tumor hypoglycemia (NICTH) : NICTH is one of the major causes of fasting hypoglycemia. It has been suggested that the hypoglycemia in the NICTH is related to the secretion of big IGF-II, but the mechanism of hypoglycemia is still unknown. In this syndrome, serum big IGF-II increases and the big IGF-II circulates with IGF binding proteins (IGFBPs) as a binary complex but not as the ternary complex (150 kDa) of big IGF-II-IGFBP-3-acid-labile subunit (ALS). The impaired formation of 150 kDa complex of big IGF-II could be one of the major causes of hypoglycemia. In the present study, we measured serum ALS levels by RIA, and also characterized serum ALS by Western immunoblot (WIB) to analyze the size and the quantity in 33 patients with NICTH.Serum ALS levels were significantly lower than those in normal subjects (3.5±0.5 vs 16.3±0.5 mg/L). In six patients, … More the ALS levels increased after successful tumor resection. Serum ALS in the patients with NICTH was detected as 80/78kDa duplet by WIB as same as in normal subjects, suggesting that the glycosylation of ALS was not different from that for normal subjects. These data demonstrate that the molecular weight sizes of ALS in the NICTH were the same as those in the normal subjects, and the decreased serum ALS levels could be one of the causes of impaired formation of 150kDa complex in the NICTH.To characterize big IGF-II, we studied big IGF-II in patients with NICTH by WIB using specific antibody against E10-21 (Ab E10-21) and E71-89 (Ab E71-89) of pro-IGF-II.The 14〜18 kDa protein was detected in sera from NICTH by WIB using Ab E10-21 and IGF-II antibody, respectively. When analyzed by Western immunoblot using Ab E71〜89, the 〜10 kDa protein was detected. As Ab E71-89 did not cross react with mature IGF-II, detected 10-kDa protein was thought to be C-terminal fragment of pro-IGF-II.These data suggest that big IGF-II in NICTH is not intact pro-IGF-II, but pro-IGF-II- (E1-21) generated from abnormal processing, and the C-terminal fragment is also present in the circulation.2) Clinical application of Western immunoblot (WIB) of insulin-like growth factor II using unextrated seium : To investigate big IGF-II, WIB technique has been used. In our previous study, acid-ethanol extraction of IGF-II from serum was required for electrophoresed sample. Recently, we simplified the method, and have directly used unextracted serum sample for electrophoresed sample and Mini-Gel System. Using this method, the results were the same as those by WIB using acid-ethanol extracted serum. Furthermore, time required to analysis of IGF-II was shortened (2 days vs 5 days). Thus, this WIB system enabled us to analyze easily molecular heterogeneity of IGF-II.3) Usefulness of allele-specific polymerase chain (AS-PCR) method to study for loss of imprinting of insulin-like growth factor II gene in tumors : We have examined IGF2 expression in tumors from ten NICTH using the AS-PCR method. IGF2 was expressed in all examined tumor tissues, and was expressed biallelically (LOI) in five of seven informative tumors. These data were concordant with those by Apa I digestion method. In a case of NICTH (gastric cancer) whose tumor tissues (primary and metastatic tumors) showed biallelic expression of IGF2, IGF-2 was monoallelic expressed in the non-tumor tissues by AS-PCR, but was not clearly shown by Apa digestion method. The present study show that the AS-PCR is simple and useful method to study LOI of IGF2. Less
期刊论文(34)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Hizuka N, Fukuda I, Takano K, Asakawa-Yasumoto K, Okubo Y, Demura H: "Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated."J Clin Endocrinol Metab. 83. 2875-7 (1998)
Hizuka N、Fukuda I、Takano K、Asakawa-Yasumoto K、Okubo Y、Demura H:“来自非胰岛细胞瘤低血糖患者的血清高分子量形式的胰岛素样生长因子 II 是 O-糖基化的。”J Clin
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Fukuda I, Hotta M, Hizuka N, Takano K, Ishikawa Y, Asakawa-Yasumoto K, Tagami E, Demura H: "Decreased serum levels of acid-labile subunit in patients wi anorexia nervosa."J Clin Endocrinol Metab. 84. 2034-6 (1999)
Fukuda I、Hotta M、Hizuka N、Takano K、Ishikawa Y、Asakawa-Yasumoto K、Tagami E、Demura H:“神经性厌食症患者酸不稳定亚基的血清水平降低。”J Clin Endocrinol Metab。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hizuka N: "Insulin like growth factor-I and II."Nippon Rinsho. 57 Suppl. 16-8 (1999)
Hizuka N:“胰岛素样生长因子-I 和 II。”Nippon Rinsho。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Fukuda I, et al.: "Changes in serum IGFBP-2,-3, and -6 levels in patients with chronic renal failure following renal transplantation."Growth Horm IGF Res. 8. 481-486 (1998)
Fukuda I 等人:“肾移植后慢性肾衰竭患者血清 IGFBP-2、-3 和 -6 水平的变化。”生长激素 IGF Res。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hotta M, Fukuda I, Sato K, Hizuka N, Shibasaki T, Takano K: "The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa."J Clin Endocrinol Metab.
Hotta M、Fukuda I、Sato K、Hizuka N、Shibasaki T、Takano K:“厌食症患者骨转换与体重、血清胰岛素样生长因子 (IGF) I 和血清 IGF 结合蛋白水平之间的关系
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 34 条
Study for pathophysiological significance of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs)
-
批准号:16590913
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.92万
-
财政年份:2004
-
负责人:HIZUKA Naomi
-
依托单位:
Study for pathophysiological significance insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs)
-
批准号:08671184
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1996
-
负责人:HIZUKA Naomi
-
依托单位:
Study for pathological significance of insulin-like growth factor binding proteins.
-
批准号:06671058
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.15万
-
财政年份:1994
-
负责人:HIZUKA Naomi
-
依托单位:
Study of growth hormone receptor abnormalities in short children
-
批准号:02671112
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1990
-
负责人:HIZUKA Naomi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
-
批准号:82371738
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:郑英霞
-
依托单位:
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
-
批准号:82304565
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:李瑾
-
依托单位:
放疗通过激活GSDMD诱发细胞焦亡促进肿瘤再增殖的机制研究及干预策略探讨
-
批准号:82373299
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:程进
-
依托单位:
基于“Healthy-NAT-Tumor”三维度的食管鳞癌蛋白组学数据挖掘及其临床意义研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:刘伟
-
依托单位:
TGF-β/lnc-APUE/ZEB1通路促进肝癌转移的机制及生物学意义
-
批准号:32100616
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李颂扬
-
依托单位:
血管内皮细胞源性的外泌体通过Notch信号通路增强肿瘤细胞可塑性的机制研究
-
批准号:32100627
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:张宇
-
依托单位:
SLC38A6通过调控天冬氨酸介导的嘧啶合成促进肝癌生长的机制研究
-
批准号:32100626
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:秦望舒
-
依托单位:
T细胞受体NRP1作为新型免疫检查点在去势抵抗性前列腺癌中的作用机制研究
-
批准号:32100631
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:刘飞
-
依托单位:
RAI16负调控肿瘤相关巨噬细胞c/EBPβ-TGF-β1通路抑制结直肠癌的机制研究
-
批准号:32100629
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:丁翠玲
-
依托单位:
c-Myc诱导的长链非编码RNA CILR1促进肿瘤细胞有氧糖酵解的作用及机制研究
-
批准号:32100622
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:曹利勉
-
依托单位: